Healthcare / BiotechnologyTaipei Exchange
$31.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $30.4M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$682M
P/E
30.4x
↑EV/EBITDA
16.0x
↑ROE
8.7%
↑Gross Margin
78.1%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.3%
FCF CAGR
—
FCF margin
-11.1%
FCF / Net income
-0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $126.2M · net income $22.6M · FCF $-14.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $126.2M | $126.2M | $115.3M | $96.8M | $94.0M |
| Net Income | $22.6M | $22.6M | $24.3M | $21.5M | $18.7M |
| EBITDA | $38.0M | $38.0M | $42.1M | $39.9M | $40.6M |
| EPS | — | — | 1.20 | 1.03 | 0.90 |
| Gross Margin | 78.1% | 78.1% | 73.8% | 72.8% | 64.5% |
| Operating Margin | 19.5% | 19.5% | 24.0% | 26.3% | 25.3% |
| Net Margin | 17.9% | 17.9% | 21.1% | 22.2% | 19.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.01 | 0.03 | 0.05 |
| Cash Flow | |||||
| Free Cash Flow | $-14.0M | $-14.0M | $30.4M | $30.8M | $23.0M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 9.7% | 10.4% | 10.1% |
| Valuation | |||||
| P/E | 30.39 | 30.39 | 25.07 | — | — |
| EV/EBITDA | 16.05 | 16.05 | 12.60 | — | — |
| P/B | 2.62 | 2.62 | 2.61 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 9.5% | 9.5% | 19.1% | 3.0% | — |
| EPS Growth | — | — | 17.0% | 14.4% | — |
| Dividend Yield | 1.9% | 1.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.20 → n/d
Residual
-10.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.